Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787

Status	RECRUITING
Phase	Phase 2
Sponsor	Alexion Pharmaceuticals, Inc.
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (7)

- Participants who have a documented diagnosis of PMN, established by positive antiPLA2R antibody level (\> 50 RU/mL) at Screening, which must be confirmed by a central laboratory
- Participants are willing to receive the background Standard of Care (SoC)
- Participants at high risk for disease progression, defined as:
- Receiving ACE inhibitor or ARB for a minimum of 8 weeks prior to Screening, with the dose titrated to the maximally tolerated level. Participants with less than 8 weeks on ACE inhibitor or ARB before Screening or who have not yet reached maximally tolerated dose will enter the Run-in Period.
- Participants who are on ACE inhibitor or ARB for a minimum of 8 weeks with Systolic Blood Pressure \< 140 mmHg in e 75% of the readings within last 8 weeks.

... and 2 more (see full listing online)

Exclusion (9)

- Estimated glomerular filtration rate (GFR) \< 60 mL/min/1.73 m\^2 during Screening
- Documented rapid deterioration of kidney function
- History of life-threatening Nephrotic Syndrome within 1 year before Screening
- Diagnosis of anti- phospholipase A2 receptor (PLA2R) negative membranous nephropathy (MN) or anti-PLA2R positive MN but Screening serum anti-PLA2R \< 50 RU/mL or kidney disease other than PMN
- History of kidney transplant or planned kidney transplant or dialysis during the Treatment Period

... and 4 more (see full listing online)

Locations (39 total)

Research Site, Loma Linda, California, United States
Research Site, San Diego, California, United States
Research Site, Minneapolis, Minnesota, United States
... and 36 more locations